Tags

Type your tag names separated by a space and hit enter

Generation of Transplantable Retinal Pigmented Epithelial (RPE) Cells for Treatment of Age-Related Macular Degeneration (AMD).
Methods Mol Biol. 2019; 2045:283-298.MM

Abstract

Age-related macular degeneration (AMD) is the foremost cause of blindness in people over the age of 60 worldwide. Clinically, this disease starts with distortion in central vision eventually leading to legal blindness. Vision loss has a significant impact on quality of life and incurs a substantial cost to the economy. Furthermore, AMD is a complex and progressive neurodegenerative disorder that triggers visual impairment due to the loss of retinal pigmented epithelium (RPE) and the light-sensitive photoreceptors that they support, protect and provide nutrition. Currently, there is no curative treatment for the most common form of this disease, i.e., dry AMD. A novel approach to treat AMD involves the transplantation of RPE cells derived from human induced pluripotent stem cells (iPSCs) in the outer retina. These iPSC-derived RPE cells not only show characteristics similar to native RPE but also could replace as well as regenerate damaged pathologic RPE and produce supportive growth factors and cytokines. Several clinical trials are being conducted taking advantage of a variety of cell- and tissue engineering-based approaches. Here, we present a simple, cost effective, and scalable cell-culture model for generation of purified RPE thus providing the foundation for developing an allogeneic cell therapy for AMD.

Authors+Show Affiliations

Eyestem Research, Centre for Cellular and Molecular Platforms (CCAMP), Bangalore, India.Eyestem Research, Centre for Cellular and Molecular Platforms (CCAMP), Bangalore, India.Eyestem Research, Centre for Cellular and Molecular Platforms (CCAMP), Bangalore, India. rajarshi.pal@eyestem.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29896658

Citation

Surendran, Harshini, et al. "Generation of Transplantable Retinal Pigmented Epithelial (RPE) Cells for Treatment of Age-Related Macular Degeneration (AMD)." Methods in Molecular Biology (Clifton, N.J.), vol. 2045, 2019, pp. 283-298.
Surendran H, Rathod RJ, Pal R. Generation of Transplantable Retinal Pigmented Epithelial (RPE) Cells for Treatment of Age-Related Macular Degeneration (AMD). Methods Mol Biol. 2019;2045:283-298.
Surendran, H., Rathod, R. J., & Pal, R. (2019). Generation of Transplantable Retinal Pigmented Epithelial (RPE) Cells for Treatment of Age-Related Macular Degeneration (AMD). Methods in Molecular Biology (Clifton, N.J.), 2045, 283-298. https://doi.org/10.1007/7651_2018_140
Surendran H, Rathod RJ, Pal R. Generation of Transplantable Retinal Pigmented Epithelial (RPE) Cells for Treatment of Age-Related Macular Degeneration (AMD). Methods Mol Biol. 2019;2045:283-298. PubMed PMID: 29896658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Generation of Transplantable Retinal Pigmented Epithelial (RPE) Cells for Treatment of Age-Related Macular Degeneration (AMD). AU - Surendran,Harshini, AU - Rathod,Reena J, AU - Pal,Rajarshi, PY - 2018/6/14/pubmed PY - 2020/6/25/medline PY - 2018/6/14/entrez KW - Age-related macular degeneration KW - Eye KW - Induced pluripotent stem cells KW - Retina KW - Retinal pigment epithelial cells SP - 283 EP - 298 JF - Methods in molecular biology (Clifton, N.J.) JO - Methods Mol Biol VL - 2045 N2 - Age-related macular degeneration (AMD) is the foremost cause of blindness in people over the age of 60 worldwide. Clinically, this disease starts with distortion in central vision eventually leading to legal blindness. Vision loss has a significant impact on quality of life and incurs a substantial cost to the economy. Furthermore, AMD is a complex and progressive neurodegenerative disorder that triggers visual impairment due to the loss of retinal pigmented epithelium (RPE) and the light-sensitive photoreceptors that they support, protect and provide nutrition. Currently, there is no curative treatment for the most common form of this disease, i.e., dry AMD. A novel approach to treat AMD involves the transplantation of RPE cells derived from human induced pluripotent stem cells (iPSCs) in the outer retina. These iPSC-derived RPE cells not only show characteristics similar to native RPE but also could replace as well as regenerate damaged pathologic RPE and produce supportive growth factors and cytokines. Several clinical trials are being conducted taking advantage of a variety of cell- and tissue engineering-based approaches. Here, we present a simple, cost effective, and scalable cell-culture model for generation of purified RPE thus providing the foundation for developing an allogeneic cell therapy for AMD. SN - 1940-6029 UR - https://www.unboundmedicine.com/medline/citation/29896658/Generation_of_Transplantable_Retinal_Pigmented_Epithelial__RPE__Cells_for_Treatment_of_Age_Related_Macular_Degeneration__AMD__ L2 - https://dx.doi.org/10.1007/7651_2018_140 DB - PRIME DP - Unbound Medicine ER -